Evidence map›Paper›PMID 39488665›Full record

ArticleNPJ precision oncology2024

Driver mutations associated with signatures of platinum sensitivity in germ cell tumors.

Yun Cheng Sawa, Liwei Jia, Harris Krause, Margaret Meagher, Frederick Millard, Andrew Elliott, John T Lafin, Christina Jamieson, Emmanuel S Antonarakis, Anishka D'Souza and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yun Cheng SawaDepartment of Urology, University of California San Diego, La Jolla, CA, USA.
Liwei JiaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Harris KrauseCaris Life Sciences, Irving, TX, USA.
Margaret MeagherDepartment of Urology, University of California San Diego, La Jolla, CA, USA.
Frederick MillardDepartment of Urology, University of California San Diego, La Jolla, CA, USA.
Andrew ElliottCaris Life Sciences, Irving, TX, USA.
John T LafinDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0003-2335-8999
Christina JamiesonDepartment of Urology, University of California San Diego, La Jolla, CA, USA.
Emmanuel S AntonarakisUniversity of Minnesota, Minneapolis, MN, USA.
Anishka D'SouzaCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Krinio GiannikouCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
James F AmatrudaCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Siamak DaneshmandCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-6224-9598
Rana R McKayDepartment of Urology, University of California San Diego, La Jolla, CA, USA.
Matthew OberleyCaris Life Sciences, Irving, TX, USA.
Chadi NabhanCaris Life Sciences, Irving, TX, USA.
Aditya BagrodiaDepartment of Urology, University of California San Diego, La Jolla, CA, USA. Bagrodia@health.ucsd.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We sought to evaluate the genomic and transcriptomic landscapes in primary and metastatic germ cell tumors (GCTs; N = 138) to uncover factors that drive cisplatin resistance. Prevalence was calculated for platinum-resistant alterations (PRAs; KRAS, TP53, and KIT mutations, and MDM2 amplification) and high copy number amplifications (CNA ≥ 6 copies). Tumors were designated as chemo-naïve (PreC, N = 66) or post-chemotherapy (PostC, N = 17). A transcriptomic signature associated with platinum sensitivity (PSS, high suggests increased sensitivity) was applied. KIT mutations were observed in 14.5% of primary versus 1.8% of met and 0% of lymph. TP53 mutations were identified in 10% of primary GCTs versus 17% of met and 16.7% of lymph. MDM2 CNAs were similar between sites. PRA-positive PreC GCTs had significantly lower average PSS scores compared to PRA-negative tumors. Lower PSS scores in chemo-naïve tumors were associated with PRAs, suggesting a potential mechanism for platinum resistance.

Identifiers

PMID39488665
PMCPMC11531533

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.